Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Nature Medicine

Volumn 6, Issue 7, 2000, Pages 797-801

  Chen, Minghua ^a   Ona, Victor O ^a   Li, Mingwei ^a   Ferrante, Robert J ^b,c   Fink, Klaus B ^d   Zhu, Shan ^a   Bian, Jie ^a   Guo, Lei ^a   Farrell, Laurie A ^e   Hersch, Steve M ^f   Hobbs, Wendy ^e   Vonsattei, Jean Paul ^e   Cha, Jang Ho J ^e   Friedlander, Robert M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; INTERLEUKIN 1BETA CONVERTING ENZYME; MINOCYCLINE; NITRIC OXIDE SYNTHASE; TETRACYCLINE;

ANIMAL MODEL; ARTICLE; DEGENERATIVE DISEASE; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUNTINGTON CHOREA; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CASPASE 1; CASPASE 3; CASPASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME ACTIVATION; EVALUATION STUDIES; GENE EXPRESSION REGULATION; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS MUSCULUS;

EID: 0033912716     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/77528     Document Type: Article

References (31)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
2. Alnemri, E.S. et al. Human ICE/CED-3 protease nomenclature. Cell 87, 171 (1996).
3. Friedlander, R.M. & Yuan, J. ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ. 5, 823-831 (1998).
4. Ona, V.O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
5. Goldberg, Y.P. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 13, 442-449 (1996).
6. Wellington, C.L. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167 (1998).
7. Aronson, A.L. Pharmacotherapeutics of the newer tetracyclines. J. Am. Vet. Med. Assoc. 176, 1061-1068 (1980).
8. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T. & Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA 95, 15769-15774 (1998).
9. Yrjanheikki, J. et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA 96, 13496-13500 (1999).
10. Tabrizi, S.J. et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47, 80-86 (2000).
11. Tabrizi, S.J. et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45, 25-32 (1999).
12. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
13. Davies, S.W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
14. Cha, J.H. et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA 95, 6480-6485 (1998).
15. Li, P. et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401-411 (1995).
16. Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000-2003 (1995).
17. Friedlander, R.M. et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J. Exp. Med. 185, 933-940 (1997).
18. Hara, H. et al. Inhibition of interleukin 1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA 94, 2007-2012 (1997).
19. White, J.K. et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nature Genet. 17, 404-410 (1997).
20. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
21. Forss-Petter, S. et al. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron 5, 187-197 (1990).
22. Enari, M., Talanian, R.V., Wong, W.W. & Nagata, S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380, 723-736 (1996).
23. Li, M. et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335-339 (2000).
24. Browne, S.E. et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (1997).
25. Schapira, A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta. 1366, 225-233 (1998).
26. Tewari, M. et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801-809 (1995).
27. Goulden, V., Glass, D. & Cunliffe, W.J. Safety of long-term high-dose minocycline in the treatment of acne. Br. J. Dermatol. 134, 693-695 (1996).
28. Gottlieb, A. Safety of minocycline for acne. Lancet 349, 374 (1997).
29. Bredt, D.S. & Snyder, S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA 87, 682-685 (1990).
30. Yoshida, T., Waeber, C., Huang, Z. & Moskowitz, M.A. Induction of nitric oxide synthase activity in rodent brain following middle cerebral artery occlusion. Neurosci. Lett. 194, 214-218 (1995).
31. Ferrante, R.J. et al. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 3052-3063 (1997).